China’s CDE approves Alphamab’s IND to begin Phase I/II trial of JSKN033
China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s ...
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...
Pharmabiz35 分钟
AstraZeneca, Daiichi Sankyo voluntarily withdrawn the MAA in the EU for datopotamab ...
Datopotamab deruxtecan has been granted Breakthrough Therapy Designation by the US Food and Drug Administration for the treatment of adult patients with locally advanced or metastatic epidermal growth ...